WallStSmart

Curis Inc (CRIS)vsRevolution Medicines Inc (RVMD)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Curis Inc generates 481% more annual revenue ($4.31M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. CRIS earns a higher WallStSmart Score of 34/100 (F).

CRIS

Avoid

34

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 8.3Quality: 5.0
Piotroski: 4/9Altman Z: -88.09

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CRISUndervalued (+80.8%)

Margin of Safety

+80.8%

Fair Value

$5.53

Current Price

$0.83

$4.70 discount

UndervaluedFair: $5.53Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CRIS3 strengths · Avg: 9.7/10
P/E RatioValuation
0.2x10/10

Attractively priced relative to earnings

Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.229/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

CRIS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.01M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-166.6%2/10

ROE of -166.6% — below average capital efficiency

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.9x4/10

Trading at 16.9x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : CRIS

The strongest argument for CRIS centers on P/E Ratio, Price/Book, Debt/Equity.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : CRIS

The primary concerns for CRIS are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

CRIS carries more volatility with a beta of 3.00 — expect wider price swings.

CRIS is growing revenue faster at -66.0% — sustainability is the question.

CRIS generates stronger free cash flow (-10M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CRIS scores higher overall (34/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Curis Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. The company is headquartered in Lexington, Massachusetts.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?